S&P Futures
4,064.00 +8.25 (+0.20%) Dow Futures
32,610.00 +10.00 (+0.03%) Nasdaq Futures
12,320.75 +41.50 (+0.34%) Russell 2000 Futures
1,841.60 +5.30 (+0.29%) Crude Oil
113.18 -0.91 (-0.80%) Gold
1,862.20 +8.30 (+0.45%)
Graphite Bio, Inc. (GRPH)
Pre-Market:
Chart Events
Performance Outlook
| Previous Close | 2.1900 |
| Open | 2.2000 |
| Bid | 2.2000 x 2900 |
| Ask | 2.3900 x 2200 |
| Day's Range | 2.1900 - 2.3600 |
| 52 Week Range | 2.0700 - 34.0000 |
| Volume | |
| Avg. Volume | 554,285 |
| Market Cap | 131.012M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.8500 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 13.00 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for GRPH
Related Research
- Graphite Bio, Inc.Analyst Report: CRISPR Therapeutics AGCRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR’s most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.RatingFair ValueEconomic Moat17 days agoMorningstar
- Business Wire
Graphite Bio Presents Preclinical Gene Replacement Data for GPH102 for Beta-thalassemia at the ASGCT 25th Annual Meeting
SOUTH SAN FRANCISCO, Calif., May 16, 2022--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to develop therapies with the potential to treat or cure serious diseases, today presented preclinical data for GPH102, the company’s differentiated gene replacement program for beta-thalassemia, in an oral presentation at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting. The hyb
- Business Wire
Graphite Bio Reports Recent Business Progress and First Quarter 2022 Financial Results
SOUTH SAN FRANCISCO, Calif., May 12, 2022--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to develop therapies with the potential to treat or cure serious diseases, today reported recent business progress and first quarter 2022 financial results.
- Simply Wall St.
Graphite Bio (NASDAQ:GRPH) Is In A Good Position To Deliver On Growth Plans
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
